Neuropathic Pain Clinical Trial
Official title:
Patterns of Cerebral Activation to Innocuous and Noxious Heat Stimulations in Neuropathic Pain
Patients with neuropathic pain exhibit hyperalgesia and allodynia. Although both peripheral and central determinants are recognized for the pathophysiological basis of neuropathic pain following peripheral injury, the modulating effect on pain processing in brain by peripheral mechanisms remains elusive. Here, we will systematically compare the sensory symptoms and brain activation to innocuous and noxious thermal stimulation applied to the distal leg, foot dorsum or forearm between patients with peripheral neuropathy and healthy controls. Functional magnetic resonance imaging will be used to define brain activation to somatic stimulation with noxious and innocuous stimuli. The blood-oxygenation-level-dependent signals will be correlated with visual analogue scale scores and sensory and affective components obtained from the Short-Form McGill Pain Questionnaire. Brain activation during thermal stimulation in patients with neuropathic pain will be clarified, and we will also analyze the potential relationships between the topography, quality and intensity of the different painful symptoms (i.e. spontaneous ongoing pain, paroxysmal pain, allodynia, hyperalgesia) and the magnitude and pattern of brain activation during thermal stimulation. This will add in our understanding in the pathophysiology of brain modulation in pain and provide clinically useful message toward the potential therapeutics in the management of neuropathic pain.
Many patients with neuropathic pain exhibit hyperalgesia and allodynia. In various pain
syndromes, neuropathic pain is among the most difficult to treat. Previous studies show that
the development of secondary hyperalgesia results from abnormal processing of nociceptor
input after injuries of the peripheral nervous system. However, the modulating effect on
pain processing in brain by peripheral mechanisms remains elusive, and only few studies
investigate the issue.
Evidences suggest that lesions of the spinothalamocortical pathway may be necessary for
developing the central pain, indicating indirect changes in excitability due to alterations
of pain modulatory systems. Previous anatomical, physiological, and lesion studies have
revealed an extensive cortical network associated with sensory, cognitive, and affective
aspects of pain, including primary somatosensory cortex, secondary somatosensory cortex,
insular cortex, and anterior cingulate cortex. Moreover, a recent study reported that
neuropathic pain might influence brain organization. Therefore, it would be intriguing to
know whether and how the brain processes pain in patients with neuropathic pain.
We hypothesize that neuropathic pain elicited by the peripheral neuropathy results in
hyperexcitability of the pain matrix (i.e. central sensitization) due to alterations of pain
modulatory systems. Patients with peripheral neuropathy and healthy volunteers will be
recruited in this study. Peripheral neuropathy is defined according to the neuropathic
symptoms and signs. For healthy volunteers, clinical history will be evaluated by
questionnaires and neurological examinations to exclude any neuropsychiatric disorder or
pain condition.
To assess the severity of different neuropathic symptoms,patients with neuropathic pain will
fill out the Neuropathic Pain Symptom Inventory (NPSI). Each subject will receive detailed
sensory examination to evaluate the integrity of small-diameter and large-diameter sensory
fibers. To measure thresholds of thermal and vibratory sensations, we will perform
quantitative sensory testing (QST) by the method of level using a Thermal Sensory Analyser
and Vibratory Sensory Analyser (Medoc Advanced Medical System, Minneapolis, MN, USA)
following an established protocol. Thermal thresholds will be recorded on the toe, and
vibratory thresholds recorded on the lateral malleolus. These values will be compared with
normative values for the age, which had been documented previously.
Functional magnetic resonance imaging (fMRI) will be performed on a 3-T MR machine (Trio;
Siemens, Erlangen, Germany). A high resolution T1 weighted scan of the entire brain in
trans-axial orientation will be obtained to provide anatomical information for the
superimposed functional activation maps. Echo Planar Imaging will be used for the
acquisition of the functional data.
We will use a CHEP stimulator (Medoc Ltd, Ramat Yishai, Israel) to deliver thermal
stimulation. The 27 mm diameter thermode is comprised of a heating thermofoil (Minco
Products, Inc., Minneapolis, MN) that is covered with a thermoconductive plastic. The
stimulus temperatures given throughout this report will be referred to the temperature of
the thermofoil. Cooling will begin immediately following attainment of the pre-fixed target
temperature. Individual heat pain threshold (HPT) will be measured before fMRI scans.
Noxious heat and innocuous heat will be applied within the distal leg, foot dorsum or
forearm. The thermode will be remained at the same site during each block of functional MRI
scans. Several pretests will be applied before CHEP recording to eliminate expectation
effects. To avoid sensitization and desensitization, low intensity stimuli will precede high
intensity stimuli at each block.
Each imaging session will be consisted of one high-resolution anatomical scan and three
functional scanning runs, with 5-min intersession interval. During the scanning, five
thermal stimuli will be applied by CHEP stimulator to the right dorsal foot. To avoid
sensitization, habituation and tissue damage, the stimulation temperature will be applied in
a random fashion, and the stimulation site will be changed slightly after each stimulus.
After 12-s stimulation, the temperature will be cooling, with a subsequent 36-s
interstimulus interval. After each fMRI session, subjects will be asked to rate the
intensity and unpleasantness of received pain stimulus. The average rating values will be
indicated after the scan on a computer driven visual analogue scale (VAS) ranging from 0 to
10 (0, no sensation; 1, slight intense; 2, innocuous warmth; 3, innocuous heat; 4, slight
pain; 5, mild pain; 7, moderate-strong pain; 9, severe pain; 10, unbearable pain), and the
intensity and unpleasantness of received pain will be assessed using the Short-Form McGill
Pain Questionnaire (SFMPQ).
All data will be processed using the Statistical Parametric Mapping software (SPM2, Wellcome
Department of Cognitive Neurology, London UK). fMRI data series will be realigned and
resliced with sinc interpolation to correct for motion artifacts. Scans with sudden head
movements of more than 2 mm will be omitted. To enable intersubject analysis, the functional
data will be coregistered to the anatomical scan and transformed into a reference space
according to the MNI template of SPM2 by normalization using sinc interpolation. This
template has been determined from 305 MRI scans of healthy subjects at the Montreal
Neurological Insitute. The resampled voxel volume of the normalized images is 2 x 2 x 2 mm.
Subsequently, data will be smoothed with an isotropic Gaussian kernel of 8 mm full-width at
half maximum to reduce high frequency noise and to account for anatomical variances.
Condition-specific effects will be estimated with the general linear model using a boxcar
approach convolved with the hemodynamic response function. High pass filtering will remove
low frequency noise and low pass filtering will account for serial autocorrelations of the
data.
We will analyze the data on an individual (subject per subject) basis and across subjects
(group analysis) using a cross-subjects variance (random effect analysis). We will compute
different contrasts between cerebral responses during innocuous and noxious heat
stimulation. Data from each stimulation will be pooled for group statistical comparisons. A
group activation map will be constructed by performing a conjunction analysis to measure the
spatial overlap of activation across subjects. A single design matrix, including 3 sessions
of all subjects, will be generated due to the limited number of experiments representing a
fixed-effects model analysis. Statistical parametric maps will be generated as t-contrasts
and corrected for multiple comparisons according to the random field theory with P < 0.05.
The threshold for the Z maps is 3.09 (P < 0.001) for individual subject analysis.
Significant clusters have to show a minimum extension volume of 10 voxels. For group
analysis, parametric maps will be constructed using the same contrast and spatial extent but
we will use a corrected threshold of P < 0.05.
;
Observational Model: Cohort, Time Perspective: Cross-Sectional
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04699734 -
Peripheral Nerve Block in Patients With Painful Diabetic Polyneuropathy
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Completed |
NCT05235191 -
Effectiveness and Safety of Methadone Versus Placebo for the Control of Neuropathic Pain in Different Etiologies
|
Phase 3 | |
Completed |
NCT05845177 -
Persistent Pain After Hip Replacement
|
||
Completed |
NCT05496205 -
A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
|
Phase 1 | |
Not yet recruiting |
NCT05949554 -
Electroencephalographic (EEG) Profils for Patients on Intravenous Ketamine.
|
||
Withdrawn |
NCT05052645 -
Ear Acupuncture for Neuropathic Pain
|
N/A | |
Completed |
NCT02866396 -
Impact of Pregabalin in Chronic Users vs. a Perioperative Limited Prescription on Oxycodone Requirement
|
||
Completed |
NCT02824588 -
Working Memory Training for Chronic Neuropathic and Fibromyalgia Pain
|
N/A | |
Completed |
NCT02930551 -
Neuromas as the Cause of Pain
|
N/A | |
Active, not recruiting |
NCT02560545 -
Cannabinoids Effects on the Pain Modulation System
|
N/A | |
Enrolling by invitation |
NCT02485795 -
Observational Study of the Impact of Genetic Testing on Healthcare Decisions and Care in Interventional Pain Management
|
N/A | |
Completed |
NCT02099890 -
The Effect of Diet on Chronic Inflammation and Related Disorders Following Spinal Cord Injury
|
Phase 3 | |
Not yet recruiting |
NCT02246517 -
The Effect of N2O on Chronic Neuropathic Pain Patients
|
Phase 0 | |
Completed |
NCT01946555 -
Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain
|
N/A | |
Completed |
NCT01884662 -
Virtual Walking for Neuropathic Pain in Spinal Cord Injury
|
N/A | |
Completed |
NCT01718821 -
Assessments on Current Pain Managements in Upper Gastrointestinal Cancer Patients
|
N/A | |
Completed |
NCT01669967 -
The Role of Intravenous (IV) Lidocaine in the Management of Chronic Neuropathic Pain of Peripheral Nerve Origin
|
N/A | |
Completed |
NCT01201317 -
A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy
|
Phase 2 | |
Completed |
NCT01207596 -
Evaluating the Efficacy and Safety of Extended Release Hydromorphone (Exalgo) in Patients With Neuropathic Pain
|
Phase 4 |